Cellular Adjuvants for Viral Infection
US-2024299521-A1 · Sep 12, 2024 · US
Vaccine
US10166279B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10166279-B2 |
| Application number | US-201414769342-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 20, 2014 |
| Priority date | Feb 20, 2013 |
| Publication date | Jan 1, 2019 |
| Grant date | Jan 1, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A mutant of an E coli heat-stable toxin (ST) having the following wild-type sequence: NSSNYCCELCCNPACTGCY wherein the mutant comprises a mutation selected from the group consisting of: A14H, A14T and N12T.
First claim
Opening claim text (preview).
The invention claimed is: 1. A mutant of an E. coli heat-stable toxin (ST) having the following wild-type sequence: NSSNYCCELCCNPACTGCY (SEQ ID NO: 1) wherein the mutant has one or two mutations, and wherein the mutant comprises a mutation selected from the group consisting of: A14T and N12T. 2. The mutant according to claim 1 wherein the mutant comprises an A14T mutation. 3. The mutant according to claim 1 wherein the mutant has a first mutation that is A14T and a second mutation selected from N12K, N12V, N12T, N12E, N12R, N12S, N12G, N12A, N12W, N12Q, L9G, L9S, L9A, L9E, L9P, L9D, L9R, P13A, P13F, P13E, C11H, E8R, and E8K. 4. The mutant according to claim 1 wherein the mutant has a first mutation that is N12T and a second mutation selected from A14T, A14H, A14Q, A14R, A14E, A14I, A14L, A14K, A14W, A14N, A14M, A14D, A14F, A14V, A14Y, A14C, L9G, L9S, L9A, L9E, L9P, L9D, L9R, P13A, P13F, P13E, C11H, E8R, and E8K. 5. The mutant according to claim 1 further comprising a T16A mutation. 6. The mutant according to claim 3 wherein the mutant has the following mutations: A14T and N12K. 7. The mutant according to claim 1 wherein the mutant has a single A14T point mutation. 8. A mutant of an E. coli heat-stable toxin (ST) having the following wild-type sequence: NSSNYCCELCCNPACTGCY (SEQ ID NO:1) wherein the mutant has two mutations, and wherein the mutant has a mutation at position T16 in combination with a mutation at position N12 or A14. 9. The mutant according to claim 8 having a T16A mutation in combination with a mutation selected from A14T, A14H, A14Q, A14R, A14E, A14I, A14L, A14K, A14W, A14N, A14M, A14D, A14F, A14V, and A14Y. 10. The mutant according to claim 8 having a T16A mutation in combination with a mutation selected from N12K, N12V, N12T, N12E, N12R, N12S, N12G, N12A, N12W and N12Q. 11. The mutant according to claim 8 wherein the mutant has the following mutations: A14T and T16A. 12. The mutant according to claim 8 wherein the mutant has the following mutations: N12K and T16A. 13. A mutant of an E. coli heat-stable toxin (ST) having the following wild-type sequence: NTFYCCELCCNPACAGCY (SEQ ID NO: 2) wherein the mutant has one or two mutations, and wherein the mutant comprises a mutation selected from the group consisting of: A13T and N11T. 14. The mutant according to claim 13 wherein the mutant comprises an A13T mutation. 15. The mutant according to claim 13 wherein the mutant has a first mutation that is A13T and a second mutation selected from N11K, N11V, N11T, N11E, N11R, N11S, N11G, N11A, N11W, N11Q, L8G, L8S, L8A, L8E, L8P, L8D, L8R, P12A, P12F, P12E, C10H, E7R, and E7K. 16. The mutant according to claim 13 wherein the mutant has a first mutation that is N11T and a second mutation selected from A13T, A13H, A13Q, A13R, A13E, A13I, A13L, A13K, A13W, A13N, A13M, A13D, A13F, A13V and A13Y. 17. The mutant according to claim 15 wherein the mutant has the following mutations: A13T and N11K. 18. The mutant according to claim 13 wherein the mutant has a single A13T point mutation. 19. A mutant according to claim 1 , 8 , or 13 , wherein the mutant is coupled to a carrier. 20. A vaccine composition comprising the mutant according to claim 1 , 8 , or 13 , and a pharmaceutically acceptable carrier or excipient.
Assignees
Inventors
Classifications
Escherichia (G) · CPC title
- A61K39/0258Primary
Escherichia · CPC title
Bacterial cells; Fungal cells; Protozoal cells · CPC title
Escherichia (G) · CPC title
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10166279B2 cover?
- A mutant of an E coli heat-stable toxin (ST) having the following wild-type sequence: NSSNYCCELCCNPACTGCY wherein the mutant comprises a mutation selected from the group consisting of: A14H, A14T and N12T.
- Who is the assignee on this patent?
- Bergen Teknologioverfoering As, The Administrators Of The Tulane Educational Fund, Bergen Teknologioverfoering
- What technology area does this patent fall under?
- Primary CPC classification A61K39/0258. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).